Company

Product

Description

Indication

Status

Orion Biotechnology Canada Ltd., of Ottawa, Ontario

OB-002H gel

Topical formulation of chemokine analogue that binds to CCR5 receptors

HIV infection prevention

Polish National Regulatory Agency and Local Ethics Committee cleared OB-002H-101 phase I study to start screening and enrollment of 30 healthy volunteers to receive either single or multiple vaginal or rectal doses


Notes

For more information about individual companies and/or products, see Cortellis.

No Comments